Provectus Biopharmaceuticals, Inc. (PVCT)

OTCMKTS: PVCT · Delayed Price · USD
0.0530
-0.0015 (-2.75%)
May 25, 2022 4:00 PM - Market closed
Market Cap22.23M
Revenue (ttm)187,605
Net Income (ttm)-5.54B
Shares Out419.45M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume114,571
Open0.0540
Previous Close0.0545
Day's Range0.0530 - 0.0550
52-Week Range0.0420 - 0.0780
Beta0.14
Analystsn/a
Price Targetn/a
Earnings Daten/a

About PVCT

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosa...

IndustryPharmaceuticals
Founded2002
Employees4
Stock ExchangeOTCMKTS
Ticker SymbolPVCT
Full Company Profile

Financial Performance

Financial Statements

News

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for...

KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/204,832, “Co...

3 weeks ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at A...

KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of Provect...

4 weeks ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunot...

KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319, “Compos...

4 weeks ago - GlobeNewsWire

Provectus Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Spl...

KNOXVILLE, TN, April 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that, in conjunction with the filing of the Company's preliminary 2022 proxy statement (Pre-14A), Provectus' Boa...

1 month ago - GlobeNewsWire

Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company's Scientific Advisory Board. Dr. Narendran is a professor ...

1 month ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for...

KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose bengal ...

1 month ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer ...

KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for ...

2 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation ...

KNOXVILLE, TN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of uveal...

3 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association ...

KNOXVILLE, TN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose bengal ...

3 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2...

KNOXVILLE, TN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium), whic...

3 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Publication of Pharmaceutical-Grade Rose Bengal's Activity Against Gram-Positi...

KNOXVILLE, TN, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on a formulation of the Company's pharmaceutical-grade rose bengal against Gram-positiv...

4 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keyt...

KNOXVILLE, TN, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated response, safety, and immune correlative data from the Company's ongoing Phase 1b clinical trial of ...

6 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR...

KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer immunotherapy PV...

7 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 ...

KNOXVILLE, TN, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium) fo...

8 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract at European Society for Me...

KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal disodium) for...

10 months ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at Ameri...

— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested

11 months ago - GlobeNewsWire

State of Tennessee Awards Funding for Public-Private Partnership to Study Animal Cancers and Dermatological Disorders...

KNOXVILLE, TN, May 25, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the State of Tennessee, as part of its fiscal year 2021-2022 budget, has directed funding in the amount of $2...

1 year ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical O...

— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693 0 67)

1 year ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immun...

KNOXVILLE, TN, March 31, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Melanoma Research had published results from an investigator-led, single-center study of Australian in-tran...

1 year ago - GlobeNewsWire

Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent for...

KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/678,133, w...

1 year ago - GlobeNewsWire

Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and...

KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which c...

1 year ago - GlobeNewsWire

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of PV-10® Immunoth...

KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investigational aut...

1 year ago - GlobeNewsWire